# Palbociclib plus Fulvestrant Clinical Outcomes PALOMA-3

## In the PALOMA-3 trial, palbociclib plus fulvestrant improved progression-free survival by approximately 5 months, overall survival by 6.9 months, and doubled time to chemotherapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer progressing on prior endocrine therapy, with a manageable safety profile dominated by reversible hematologic toxicity.

## Abstract

The PALOMA-3 trial demonstrated substantial clinical benefit for palbociclib plus fulvestrant in hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. Across multiple analyses with follow-up extending to 73.3 months, palbociclib plus fulvestrant consistently improved median progression-free survival by approximately 5 months compared to placebo plus fulvestrant (9.2-11.2 months vs 3.8-4.6 months, HR 0.42-0.50, p<0.001). The most recent analysis showed median overall survival of 34.8 months versus 28.0 months (HR 0.81, 95% CI 0.65-0.99), with greater benefit observed in patients with endocrine-sensitive disease who had not received prior chemotherapy for metastatic disease (39.3 vs 29.7 months, HR 0.72). Palbociclib plus fulvestrant doubled the median time to receipt of chemotherapy (17.6 vs 8.8 months, HR 0.58, p<0.001).

The safety profile was characterized by predictable hematologic toxicity, with grade 3-4 neutropenia occurring in 52-65% of patients but febrile neutropenia remaining low at 0.6-4.1%. Treatment discontinuation rates due to adverse events were minimal (2.0-2.6%), and dose intensity was maintained at 89.7% despite frequent dose modifications. Clinical benefit was consistent across menopausal status, geographic populations including Asian patients (HR 0.485), and molecular subtypes, with palbociclib providing benefit regardless of ESR1, PIK3CA, or TP53 mutation status. Quality of life was maintained with no significant deterioration from baseline.

## Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Records from Elicit search

- n = 200

Papers screened using:

- Patient Population - Disease Type
- Intervention Type
- Clinical Outcomes Reported
- Study Design
- Patient Age
- Combination Therapy Focus
- Human Clinical Evidence
- Full Publication Available

- n = 190 (Papers screened out)
- n = 10 (Papers included for extraction)

## Data extraction

### Efficacy Outcomes:
- Primary endpoint results (progression-free survival): median PFS, hazard ratio, 95% CI, p-value
- Secondary efficacy endpoints (overall survival, overall response rate, clinical benefit rate): median values, hazard ratios, 95% CIs, p-values

### Safety Profile:
- Most common adverse events (any grade and grade 3-4) with percentages for each treatment arm
- Treatment exposure and relative dose intensity

### Patient Characteristics:
- Sample size per treatment arm
- Demographics (median age, menopausal status distribution)
- Disease characteristics (HR/HER2 status, visceral disease percentage)

### Subgroup Analyses:
- Result breakdowns for pre-specified subgroups including endocrine sensitivity, menopausal status, and geographic populations

### Follow-up Duration:
- Median follow-up duration for the overall population
- Percentage of events observed for primary and secondary endpoints

### Treatment Details:
- Dosing regimens for palbociclib and fulvestrant
- Treatment duration (median time on treatment)

## Results

### Overall Survival
Overall survival (OS) analyses evolved with longer follow-up showing median OS of 34.8 months for palbociclib plus fulvestrant versus 28.0 months for placebo plus fulvestrant.

### Safety and Tolerability
The safety profile of palbociclib plus fulvestrant was characterized predominantly by asymptomatic hematologic toxicity. Neutropenia occurred early, with median onset time for first episode of grade ≥3 neutropenia of 15 days and median duration of 7 days.

### Subgroup Analyses
Subgroup analyses demonstrated consistent benefit of palbociclib plus fulvestrant across pre-specified stratification factors.

### Biomarker Analyses
Circulating tumor DNA (ctDNA) analyses yielded important prognostic information.

## Patient-Reported Outcomes
Patient-reported outcomes showed that global quality of life was maintained with no statistically significant changes from baseline observed for patient-reported outcome scores.

## Synthesis
The PALOMA-3 trial demonstrated consistent and clinically meaningful benefit of adding palbociclib to fulvestrant in hormone receptor-positive, HER2-negative metastatic breast cancer across multiple analyses spanning over 6 years of follow-up.